ArticleMethodsX2022
The LC-QTOF-MS/MS analysis of acid degradation products of Rifaximin, an antibiotic.
Article in MethodsX, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 6 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present research aims to propose a simple and accurate technique for the analysis of Rifaximin in the presence of its stress degradation products and analysis of degradation products by LC-MS/MS analysis. Rifaximin was submitted to forced degradation under the acid hydrolysis condition as prescribed by the ICH. The extract was prepared by firstly treated with HCl and heated about 4 to 8 h. The filtrate was collected and separated using dichloromethane followed by evaporation in rotary evaporator to obtain a solid crude extract which was then stored under refrigeration at -80 °C. Liquid chromatography quadrupole time-of-flight mass spectrometry (LC-QTOF-MS/MS) was utilized to identify products in the drug sample. The data processing results revealed the presence of 9 products in the degraded sample of Rifaximin. This data article contains the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.